In	re	App	lication	of:
----	----	-----	----------	-----

University of Southern

California

Inventors:

Assignor:

Peter C. Brooks

Eric Petitclerc Jingsong Xu

Application No: 09/478,977

Filed:

January 6, 2000

For:

METHOD AND COMPOSITION FOR ANGIOGENESIS INHIBITION

Group Art Unit:

1642

COPY OF PAPE ORIGINALLY FILED

Examiner:

A. Harris

Certificate of Mailing Under 37 C.F.R. § 1.8

Pursuant to 37 C.F.R. § 1.8, I hereby certify that this paper and all enclosures are being deposited with the United States Postal Service as first class mail on the date indicated below in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Date: December 5, 2001

Type or Print Name of Person Mailing: Lawrence Barrett

Signature of Person Mailing

INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with 37 C.F.R. § 1.56, the references listed on the attached Form PTO-1449 are being brought to the attention of the Examiner for consideration in connection with the examination of the above-identified patent application.

I. Timing of the Information Disclosure Statement:

This Information Disclosure Statement is filed:

With the new patent application submitted herewith (37 C.F.R. § 1.97(a)).
Within three months after the filing date of the application or within three months
after the date of entry of the national stage of a PCT application as set forth in
37 C.F.R. § 1.491.
Before the mailing of a first Office Action after the filing of a request for
continued examination under 37 C.F.R. § 1.114.
Before the mailing of a first Office action on the merits. In the event, however,
that an Office Action has crossed in the mail with this Information Disclosure
Statement:

		the Commissioner is hereby authorized to charge Deposit Account				
		No. 50-1192, Docket No for the fee (\$180) set forth				
		in 37 C.F.R. § 1.17(p) and any additional required fees.				
		a statement as specified in 37 C.F.R. § 1.97(e) is provided below.				
This Informat	This Information Disclosure Statement is filed:					
	filing d Office is know	he first Office Action and more than three months after the application's late; or PCT national stage date of entry filing, or after the mailing of a first Action after the filing of a request for continued examination, but, as far as vn to the undersigned, prior to the mailing date of either a final rejection or e of allowance, whichever occurs first, and				
		the Commissioner is hereby authorized to charge Deposit Account No. 50-1192 for the fee (\$180) set forth in 37 C.F.R. § 1.17(p) and any additional required fees.				
		a statement as specified in 37 C.F.R. § 1.97(e) is provided below.				
This Information Disclosure Statement is filed:						
	After the mailing date of either a final rejection or a notice of allowance, whichever occurred first, but on or before the payment of an issue fee, and is accompanied by the fee (\$180.00) set forth in 37 C.F.R. § 1.17(i)(1) and a certification as specified in 37 C.F.R. § 1.97(e), as checked below. This document is to be considered as a petition requesting consideration of the Information Disclosure Statement.					
Pursuant to 37	C.F.R.	§ 1.97(e), the undersigned certifies that:				
	first cit	em of information contained in the Information Disclosure Statement was sed in any communication mailed from a foreign patent office in a repart foreign application not more than three months prior to the filing of formation disclosure statement.				
	cited in foreign reasona 37 C.F	n of information contained in this information disclosure statement was a communication mailed from a foreign patent office in a counterpart application or, to the knowledge of the undersigned after making able inquiry, was known to any individual designated in R. § 1.56(c) more than three months prior to the filing of this Information statement.				

II. Copies of the Cited Items:				
	\boxtimes	Copies of all of the items listed on the attached Form PTO-1449 are enclosed.		
		Copies of only the following items listed on the attached Form PTO-1449 are enclosed:		
		Copies of those items which are marked with an asterisk (*) in the attached Form PTO-1499 are not supplied because they were previously cited by or submitted to the Patent Office in a prior Application No, filed and relied upon in this application for an earlier filing date under 35 U.S.C. § 120. See 37 C.F.R. § 1.98(d).		
		Copies of those items which are marked with an asterisk (**) in the attached Form PTO-1499 were cited in a foreign examination report in a related case. A copy of the search report and the cited references not already of record in this application are attached hereto.		
III. Concise Explanation of Relevance:				
	\boxtimes	A concise explanation of relevance of the items listed on Form PTO-1449 is not given.		
		A concise explanation of relevance of [some of] the items listed on Form PTO-		
		1449 is in the form of an English language copy of a Search Report from a foreign		
		patent office, issued in a counterpart application, which refers to the relevant		
		portions of the references (copy attached).		

IV. Conclusion:

Citation of the above documents shall not be construed as:

- 1. an admission that the documents are necessarily prior art with respect to the instant invention;
- 2. a representation that a search has been made, other than as described above; or
- an admission that the information cited herein is, or is considered to be, material to patentability as defined in § 1.56(b).

It is respectfully requested that the Examiner indicate consideration of the cited references by returning a copy of the attached form PTO 1449 with initials or other appropriate marks.

The Commissioner is hereby authorized to charge Deposit Account No. 50-1192 Docket No.: 13761-0727 for any additional fees required in connection with the filing of this Information Disclosure Statement.

DATE: December 5, 2001

Respectfully submitted,

Rajiv Yadav, R.D., Esq.

Registration No.: 43,999

McCutchen, Doyle, Brown & Enersen, LLP Three Embarcadero Center, 18th Floor San Francisco, California 94111

Telephone: (415) 393-2000 Telefax: (415) 393-2286